Literature DB >> 33734563

Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.

Sebastian Kehrloesser1, Simon Oberst2,3, Willien Westerhuis4, Astrid Wendler1, Anke Wind5, Harriët Blaauwgeers4, Jean-Benoit Burrion6, Péter Nagy7, Gunnar Saeter2,8, Eva Gustafsson9, Paolo De Paoli10, József Lovey2,7, Claudio Lombardo2, Thierry Philip2,11, Dominique de Valeriola2,6, Marjet Docter5, Femke Boomsma12, Mahasti Saghatchian13,14, Marek Svoboda15, Irene Philip16, Francesco Monetti17, Henk Hummel4, Gordon McVie18, Renée Otter, Wim van Harten2,5,19,20.   

Abstract

There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  accreditation; clinical trials; comprehensive cancer center; multidisciplinarity; quality standard; translational research

Mesh:

Year:  2021        PMID: 33734563      PMCID: PMC8096787          DOI: 10.1002/1878-0261.12950

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  24 in total

Review 1.  Has the US Cancer Centre model been 'successful'? Lessons for the European cancer community.

Authors:  Richard Sullivan
Journal:  Mol Oncol       Date:  2009-04-01       Impact factor: 6.603

2.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Overall survival before and after centralization of gastric cancer surgery in the Netherlands.

Authors:  M van Putten; S D Nelen; V E P P Lemmens; J H M B Stoot; H H Hartgrink; S S Gisbertz; E J Spillenaar Bilgen; J Heisterkamp; R H A Verhoeven; G A P Nieuwenhuijzen
Journal:  Br J Surg       Date:  2018-08-22       Impact factor: 6.939

4.  Participation of Italian Cancer Centres of the Alleanza Contro Il Cancro (ACC) in the Organisation of European Cancer Institutes (OECI) Accreditation and Designation program: a successful first national initiative.

Authors:  Simon Oberst; Femke Boomsma; Claudio Lombardo; Marjet Docter; Harriët Blaauwgeers; Paolo De Paoli; Dominique de Valeriola; Angelo Paradiso; Mahasti Saghatchian
Journal:  Tumori       Date:  2015-12-30       Impact factor: 2.098

5.  European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of Excellence.

Authors:  Ulrik Ringborg; Julio Celis; Alexander Eggermont; Anton Berns
Journal:  Eur J Cancer       Date:  2018-02-14       Impact factor: 9.162

Review 6.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.

Authors:  J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray
Journal:  Eur J Cancer       Date:  2018-08-09       Impact factor: 9.162

Review 7.  Towards a mission-oriented approach to cancer in Europe: an unmet need in cancer research policy.

Authors:  Julio E Celis; Manuel Heitor
Journal:  Mol Oncol       Date:  2019-02-01       Impact factor: 6.603

8.  Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands.

Authors:  N Haj Mohammad; N Bernards; M G H Besselink; O R Busch; J W Wilmink; G J M Creemers; I H J T De Hingh; V E P P Lemmens; H W M van Laarhoven
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-19       Impact factor: 4.553

9.  Towards a cancer mission in Horizon Europe: recommendations.

Authors:  Anton Berns; Ulrik Ringborg; Julio E Celis; Manuel Heitor; Neil K Aaronson; Nancy Abou-Zeid; Hans-Olov Adami; Kathi Apostolidis; Michael Baumann; Alberto Bardelli; René Bernards; Yvonne Brandberg; Carlos Caldas; Fabien Calvo; Caroline Dive; Angelika Eggert; Alexander Eggermont; Carolina Espina; Frederik Falkenburg; Jérôme Foucaud; Douglas Hanahan; Ulrike Helbig; Bengt Jönsson; Mette Kalager; Sakari Karjalainen; Miklós Kásler; Pamela Kearns; Klas Kärre; Denis Lacombe; Francesco de Lorenzo; Françoise Meunier; Gerd Nettekoven; Simon Oberst; Péter Nagy; Thierry Philip; Richard Price; Joachim Schüz; Eric Solary; Peter Strang; Josep Tabernero; Emile Voest
Journal:  Mol Oncol       Date:  2020-08       Impact factor: 6.603

View more
  1 in total

1.  The Porto European Cancer Research Summit 2021.

Authors:  Ulrik Ringborg; Anton Berns; Julio E Celis; Manuel Heitor; Josep Tabernero; Joachim Schüz; Michael Baumann; Rui Henrique; Matti Aapro; Partha Basu; Regina Beets-Tan; Benjamin Besse; Fátima Cardoso; Fátima Carneiro; Guy van den Eede; Alexander Eggermont; Stefan Fröhling; Susan Galbraith; Elena Garralda; Douglas Hanahan; Thomas Hofmarcher; Bengt Jönsson; Olli Kallioniemi; Miklós Kásler; Eva Kondorosi; Jan Korbel; Denis Lacombe; José Carlos Machado; José M Martin-Moreno; Francoise Meunier; Péter Nagy; Paolo Nuciforo; Simon Oberst; Júlio Oliveiera; Maria Papatriantafyllou; Walter Ricciardi; Alexander Roediger; Bettina Ryll; Richard Schilsky; Grazia Scocca; Raquel Seruca; Marta Soares; Karen Steindorf; Vincenzo Valentini; Emile Voest; Elisabete Weiderpass; Nils Wilking; Amanda Wren; Laurence Zitvogel
Journal:  Mol Oncol       Date:  2021-09-13       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.